20/20 Biolabs, Inc.AIDX
Price (close)
$0.43
Market cap
$5.5M
P/E
—
Revenue (FY)
$2.0M
Net income
-$3.7M
Dividend yield
—
1-year total return
—
Net margin
-182.8%
Revenue growth
16.7%
Debt / equity
—
What 20/20 Biolabs, Inc. does.
develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases.
offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, and (ii)
OneTest for Longevity, which measures inflammatory biomarkers, that was launched in February 2026 (the Longevity test is also being branded
Revenue and profit, by fiscal year.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | — | $1.8M | $2.0M |
| Net income | — | -$5.6M | -$3.7M |
More on AIDX.
- 20/20 Biolabs, Inc. summary
- 20/20 Biolabs, Inc. financial statements
- 20/20 Biolabs, Inc. key metrics
- 20/20 Biolabs, Inc. health scores and style box
- 20/20 Biolabs, Inc. earnings
- 20/20 Biolabs, Inc. dividends
- 20/20 Biolabs, Inc. valuation
- 20/20 Biolabs, Inc. ownership and insiders
- 20/20 Biolabs, Inc. peers
Figures from 20/20 Biolabs, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.